J. Tsurutani

VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial

Barbara Pistilli, Komal Jhaveri, S-A. Im et al. · Annals of Oncology · 2025 · 13 citations

LBA21 Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)

R.F. Salgado, A. Bardia, G. Curigliano et al. · Annals of Oncology · 2024 · 11 citations · Full text